Shows
EASL Video PodcastsEASL Studio Podcast: Endoscopic Management of Variceal Bleeding: Outdated or Evolving Beyond Tradition?This EASL Studio episode discusses cutting-edge approaches for managing bleeding varices. Explore the evolution of endoscopic therapies, the role of interventional radiology, and decision-making for high-risk gastric varices. Gain insights into EUS-guided portal pressure assessment and its impact on tailoring treatment strategies.
Moderator: Debbie Shawcross
Faculty: Wim Laleman, David Patch
Related episode
S6E14: Endohepatology: The endoscopic liver gold rush
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
2025-04-1046 minEASL Video PodcastsEASL Studio Podcast: JHEP Live: JHEP at 40: What to Expect Next?This episode celebrates 40 years of the Journal of Hepatology, EASL’s flagship journal.
Tune in to discover how far we’ve come—and what’s next for the journal.
Moderator: Thomas Berg
Faculty: Paolo Angeli, Annalisa Berzigotti, Rajiv Jalan, Vlad Ratziu, Frank Tacke and Jessica Zucman-Rossi
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
2025-04-101h 02
EASL Video PodcastsEASL Studio Podcast: Rare Liver Malignancies: Small Numbers, Big QuestionsRare liver tumors like combined HCC/CCA, fibrolamellar HCC, and haemangioendothelioma pose significant diagnostic and therapeutic challenges. In this episode, we explore the latest insights, controversies, and clinical approaches outlined in the new EASL position paper. Join us to uncover how these advancements can address key hurdles in managing these rare malignancies.
Read the position paper: Rare primary liver cancers: An EASL position paper
Moderator: Thomas Berg
Faculty: Ruben de Kleine and Henning Wege
Related episodes
S6E4: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyond
S5E13: Basi...2025-04-1045 min
EASL Video PodcastsEASL Studio Podcast: From Evidence to Action: Reducing Alcohol-Related HarmThis episode of EASL Studio explores insights from the European Alcohol Health Alliance Symposium, hosted by the WHO Regional Office for Europe in collaboration with EASL. Topics include managing alcohol marketing strategies, addressing gaps in cancer-related labelling, and understanding the influence of social norms on adolescent alcohol consumption. Learn from successful alcohol policy implementations and discover how the WHO Playbook can empower advocates to protect children and reshape public health strategies for alcohol-related harm.
Moderator: Shira Zelber-Sagi
Faculty: Frank Murray, Catherine Paradis (WHO Europe) and Debbie Shawcross
Related episodes
S7E5 Why doe...2025-04-1032 min
EASL Video PodcastsEASL Studio Podcast: Understanding Sex Disparities in MASLDMetabolic dysfunction-associated steatotic liver disease (MASLD) affects men and women differently, yet sex-based differences remain poorly explored. In the week celebrating International Women’s Day, this EASL Studio episode debates the molecular, hormonal, and genetic mechanisms driving these disparities.
Moderator: Saskia van Mil
Faculty: Sara Della Torre and Münevver Demir
Related episode
S4E9 YI Choice: Gender equality in academics — reducing the gap
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
2025-04-1041 min
EASL Video PodcastsEASL Studio Podcast: Lessons from Your PET: Understanding and Evaluating Treatment for Wilson’s DiseaseTune into this EASL Studio episode to learn about the role of PET imaging in Wilson’s disease. Discover how PET advances understanding, supports treatment decisions, and enhances patient care in managing this rare liver disorder.
Moderator: Debbie Shawcross
Faculty: Aftab Ala, Zoe Mariño and Thomas Sandahl
This EASL Studio is supported by Orphalan and Univar Solutions.
EASL has received no input from Orphalan or Univar Solutions with regards to the content of this programme.
Related episodes
S4E15: Diagnostic and therapeutic challenges in Wilson’s disease
S4E7: Genet...2025-04-1039 min
EASL Video PodcastsEASL Studio Podcast: Liver Cancer Care in 2025: Progress, Hope, and What Lies AheadJoin this EASL Studio episode for a clinical perspective on advancing HCC care. Explore the realities of adjuvant therapies, emerging molecular targets, and strategies for curative conversion. Gain insights into practical innovations shaping the future and translating research into improved patient outcomes.
Moderator: Thomas Berg
Faculty: Tim Greten and Anna Saborowski
This EASL Studio is supported by Bayer.
EASL has received no input from Bayer with regards to the content of this programme.
Related episodes
EASL Studio S5E13: Basics in decision-making for liver cancer treatment
EASL Studio from EASL C...2025-04-1045 min
EASL Video PodcastsEASL Studio Podcast: YI choice: From Idea to Abstract to Publication: Navigating Your Research journeyWatch this EASL Studio to start navigating your research journey with essential tips on generating ideas, refining hypotheses, and crafting standout abstracts for EASL Congress. Discover how to choose the right journal, prepare a submission-ready manuscript, and boost your career visibility in hepatology.
Moderator: Thomas Marjot
Faculty: Marta Afonso, Emma Andersson and Paolo Angeli
Related episodes
S4E20 – COST Actions: Opportunities for pan-European collaborations in liver diseases
S4E14 – EASL-EF CLIF and EU Grants: Exploring novel mechanism and treatment of chronic liver failure
S4E2 YI Choice – How to build consortia and registries
All EAS...2025-04-1032 min
EASL Video PodcastsEASL Studio Podcast: JHEP Live – EASL CPGs on Hepatocellular Carcinoma: What’s New and How Will Practice Change?Discover the latest updates from the updated EASL Clinical Practice Guidelines on Hepatocellular Carcinoma (HCC). This episode explores key advancements, their impact on clinical practice, and how they will shape the future of HCC diagnosis, treatment, and management. Join our faculty as they break down the changes and provide practical insights for healthcare professionals.
Moderator: Thomas Berg
Faculty: Peter Galle, Josep Llovet and Lorenza Rimassa
Related episodes
EASL Studio S6E4: World Cholangiocarcinoma Day: Highlighting Guidelines and Exploring the Horizon Beyond
EASL Studio S6E9: Therapy Hierarchy in HCC: A New Kid on th...2025-04-1049 min
EASL Video PodcastsEASL Studio Podcast: 2025 Update on Steatotic Liver Disease: Rethinking Standard of CareJoin us for the season premiere of EASL Studio Season 8 as we unpack key insights from the Steatotic Liver Disease (SLD) Summit. Explore the evolving consensus on patient trajectories, advancements in ALD and MetALD treatment pathways, and the latest endpoint discussions. The episode also highlights a holistic approach to diagnosing and managing comorbidities and revisits the standard of care in light of breakthroughs in MASH treatments.
Moderator: Aleksander Krag
Faculty: Cyrielle Caussy, Sven Francque and Brian Lee
This EASL Studio is supported by Madrigal. EASL has received no input from Madrigal with regards to...2025-04-1035 min
EASL Video PodcastsEASL DeepDive: Understanding and managing PBC symptomsIn this EASL DeepDive held on 03 July 2024, Palak Trivedi, Emma Culver, Andreas Kremer and Jessica Dyson explain the risk assessment in people with PBC as well as the mechanistic and treatment of fatigue and pruritus.
Learning objectives
Discover the latest mechanistic insights relating to the occurrence of PBC symptoms
Learn more about the holistic management of PBC symptoms, with a particular emphasis on fatigue and pruritus
Learn more about the current treatment options, their efficacy and limitations
Get a detailed understanding of the drugs in the pipeline for the near future
This EASL DeepDive webinar...2025-04-041h 15
EASL Video PodcastsEASL DeepDive: Glucagon in MASH: A next step in “metabolic” drugs tackling liver disease?In this EASL DeepDive held on 30 October 2024, Henning Grønbæk, Cyrielle Caussy, Mazen Noureddin and Frank Tacke provide an understanding of the role of glucagon and glucagon-receptors in physiology and in MASH patients. Additionally, they review key clinical trials and evaluate the integration of GLP-1 receptor agonists into current EASL-EASD-EASO clinical guidelines for practical patient management.
Learning objectives:
Understand the role of glucagon and glucagon-receptor in normal physiology and disease.
Understand the rationale of a combined dual GLP-1/GCG RA and its potential benefit compared to a GLP-1RA alone and thus gain insights into th...2025-04-041h 06
EASL Video PodcastsEASL DeepDive: Evolving insights in role and management of Alpha-1 Antitrypsin DeficiencyIn this EASL DeepDive held on 06 November 2024, Alice Turner, Pavel Strnad, and Nicola Brunetti discuss and explore the changing insights in the management of Alpha-1 Antitrypsin Deficiency.
Learning objectives:
Learn more about the role of heterozygosity of alpha-1 as a risk factor for chronic liver disease, especially in the context of other causes such as MASLD or alcohol
Get a better understanding of the extrahepatic manifestations and the need for a multi-disciplinary approach
Learn more about screening: who to screen and how
Discover the general unmet needs related to AAT, with an emphasis on awareness and...2025-04-041h 07
EASL Video PodcastsEASL DeepDive: What is the future of PBC treatment?In this EASL DeepDive held on 25 February 2025, Ana Lleo, Adriaan van der Meer, Gideon Hirschfield, and Bettina Hansen explore the future of primary biliary cholangitis (PBC) treatment. Discover the emerging therapies, current challenges and personalised approaches that are shaping the management of PBC.
Learning objectives
Learn more about the molecular mechanisms underlying the disease and the potential targets for drug therapy
Get a good understanding of the efficacy of the current drugs and the potential added value of the upcoming second line treatments for PBC and where to position these new treatments in the treatment landscape
Learn more a...2025-04-0459 min
EASL PodcastsEASL DeepDive: Glucagon in MASH: A next step in “metabolic” drugs tackling liver disease?In this EASL DeepDive held on 30 October 2024, Henning Grønbæk, Cyrielle Caussy, Mazen Noureddin and Frank Tacke provide an understanding of the role of glucagon and glucagon-receptors in physiology and in MASH patients. Additionally, they review key clinical trials and evaluate the integration of GLP-1 receptor agonists into current EASL-EASD-EASO clinical guidelines for practical patient management.Learning objectives:Understand the role of glucagon and glucagon-receptor in normal physiology and disease.Understand the rationale of a combined dual GLP-1/GCG RA and its potential benefit compared to a GLP-1RA alone and thus gain in...2025-04-041h 06
EASL PodcastsEASL DeepDive: Understanding and managing PBC symptomsIn this EASL DeepDive held on 03 July 2024, Palak Trivedi, Emma Culver, Andreas Kremer and Jessica Dyson explain the risk assessment in people with PBC as well as the mechanistic and treatment of fatigue and pruritus.Learning objectivesDiscover the latest mechanistic insights relating to the occurrence of PBC symptomsLearn more about the holistic management of PBC symptoms, with a particular emphasis on fatigue and pruritusLearn more about the current treatment options, their efficacy and limitationsGet a detailed understanding of the drugs in the pipeline for the near futureThis EASL DeepDive webinar is...2025-04-041h 15
EASL PodcastsEASL DeepDive: Evolving insights in role and management of Alpha-1 Antitrypsin DeficiencyIn this EASL DeepDive held on 06 November 2024, Alice Turner, Pavel Strnad, and Nicola Brunetti discuss and explore the changing insights in the management of Alpha-1 Antitrypsin Deficiency.Learning objectives:Learn more about the role of heterozygosity of alpha-1 as a risk factor for chronic liver disease, especially in the context of other causes such as MASLD or alcoholGet a better understanding of the extrahepatic manifestations and the need for a multi-disciplinary approachLearn more about screening: who to screen and howDiscover the general unmet needs related to AAT, with an emphasis on awareness and timely...2025-04-041h 07
EASL PodcastsEASL DeepDive: What is the future of PBC treatment?In this EASL DeepDive held on 25 February 2025, Ana Lleo, Adriaan van der Meer, Gideon Hirschfield, and Bettina Hansen explore the future of primary biliary cholangitis (PBC) treatment. Discover the emerging therapies, current challenges and personalised approaches that are shaping the management of PBC.Learning objectivesLearn more about the molecular mechanisms underlying the disease and the potential targets for drug therapyGet a good understanding of the efficacy of the current drugs and the potential added value of the upcoming second line treatments for PBC and where to position these new treatments in the treatment landscapeLearn more a...2025-04-0459 min
EASL PodcastsEASL Studio Podcast: Rare Liver Malignancies: Small Numbers, Big QuestionsRare liver tumors like combined HCC/CCA, fibrolamellar HCC, and haemangioendothelioma pose significant diagnostic and therapeutic challenges. In this episode, we explore the latest insights, controversies, and clinical approaches outlined in the new EASL position paper. Join us to uncover how these advancements can address key hurdles in managing these rare malignancies.Read the position paper: Rare primary liver cancers: An EASL position paperModerator: Thomas BergFaculty: Ruben de Kleine and Henning WegeRelated episodesS6E4: World Cholangiocarcinoma Day: Highlighting guidelines and...2025-03-2744 min
EASL PodcastsEASL Studio Podcast: From Evidence to Action: Reducing Alcohol-Related HarmThis episode of EASL Studio explores insights from the European Alcohol Health Alliance Symposium, hosted by the WHO Regional Office for Europe in collaboration with EASL. Topics include managing alcohol marketing strategies, addressing gaps in cancer-related labeling, and understanding the influence of social norms on adolescent alcohol consumption. Learn from successful alcohol policy implementations and discover how the WHO Playbook can empower advocates to protect children and reshape public health strategies for alcohol-related harm.Moderator: Shira Zelber-SagiFaculty: Frank Murray, Catherine Paradis (WHO Europe) and Debbie ShawcrossRelated...2025-03-2032 min
EASL PodcastsEASL Studio Podcast: Lessons from Your PET: Understanding and Evaluating Treatment for Wilson’s DiseaseTune into this EASL Studio episode to learn about the role of PET imaging in Wilson’s disease. Discover how PET advances understanding, supports treatment decisions, and enhances patient care in managing this rare liver disorder.Moderator: Debbie ShawcrossFaculty: Aftab Ala, Zoe Mariño and Thomas SandahlThis EASL Studio is supported by Orphalan and Univar Solutions.EASL has received no input from Orphalan or Univar Solutions with regards to the content of this programme.Related episodesS4E15: Diagnostic and therapeutic challenges in...2025-03-0638 min
EASL PodcastsEASL Studio Podcast: Liver cancer care in 2025: Progress, hope, and what lies aheadJoin this EASL Studio episode for a clinical perspective on advancing HCC care. Explore the realities of adjuvant therapies, emerging molecular targets, and strategies for curative conversion. Gain insights into practical innovations shaping the future and translating research into improved patient outcomes.Moderator: Thomas BergFaculty: Tim Greten and Anna SaborowskiThis EASL Studio is supported by Bayer.EASL has received no input from Bayer with regards to the content of this programme.Related episodesEASL Studio S5E13: Basics in decision-making for liver...2025-02-2744 min
EASL PodcastsEASL Studio Podcast: YI choice: From idea to abstract to publication: Navigating your research journeyWatch this EASL Studio to start navigating your research journey with essential tips on generating ideas, refining hypotheses, and crafting standout abstracts for EASL Congress. Discover how to choose the right journal, prepare a submission-ready manuscript, and boost your career visibility in hepatology.Moderator: Thomas MarjotFaculty: Marta Afonso, Emma Andersson and Paolo AngeliRelated episodesS4E20 – COST Actions: Opportunities for pan-European collaborations in liver diseasesS4E14 – EASL-EF CLIF and EU Grants: Exploring novel mechanism and treatment of chronic liver failureS4E2 YI Choice – How to build...2025-02-2031 min
EASL PodcastsEASL Studio Podcast: JHEP Live – EASL CPGs on hepatocellular carcinoma: What’s new and how will practice change?Discover the latest updates from the updated EASL Clinical Practice Guidelines on Hepatocellular Carcinoma (HCC). This episode explores key advancements, their impact on clinical practice, and how they will shape the future of HCC diagnosis, treatment, and management. Join our faculty as they break down the changes and provide practical insights for healthcare professionals.Moderator: Thomas BergFaculty: Peter Galle, Josep Llovet and Lorenza RimassaRelated episodesEASL Studio S6E4: World Cholangiocarcinoma Day: Highlighting Guidelines and Exploring the Horizon BeyondEASL Studio S6E9: Therapy Hierarchy in...2025-02-1348 min
EASL PodcastsEASL Studio Podcast: 2025 update on steatotic liver disease: Rethinking standard of careJoin us for the season premiere of EASL Studio Season 8 as we unpack key insights from the Steatotic Liver Disease (SLD) Summit. Explore the evolving consensus on patient trajectories, advancements in ALD and MetALD treatment pathways, and the latest endpoint discussions. The episode also highlights a holistic approach to diagnosing and managing comorbidities and revisits the standard of care in light of breakthroughs in MASH treatments.Moderator: Aleksander KragFaculty: Cyrielle Caussy, Sven Francque and Brian LeeThis EASL Studio is supported by Madrigal. EASL has received no input from...2025-02-0634 min
EASL PodcastsEASL Studio Podcast: The liver as a master regulator of ageing, health, and longevityThis EASL Studio showcases cutting-edge research elucidating the role of the liver in ageing and exploring its role as a regulator of health and longevity. In particular, the liver’s function in modulating systemic ageing, its ability to buffer genetic and metabolic disturbances, and its influence on the progression of age-related diseases is discussed. Last but not least, panelists provides new insights into potential therapeutic strategies aimed at promoting healthy ageing by targeting liver-specific mechanisms.This episode is related to this study published in July 2024: Inhibition of IL-11 signalling extends mammalian healthspan and lifespanFa...2024-12-1235 min
EASL PodcastsEASL Studio Podcast: TIPS: How far can we go?This EASL Studio episode examines the current relevance of Hepatic Encephalopathy (HE) and the roles of hepatologists and interventional radiologists in patient care. The discussion covers technical approaches, patient outcomes, and the expanding indications for TIPS.Tune in to:Learn about the critical roles of hepatologists and radiologists in managing HE.Understand technical factors, including TIPS procedures and their application in modern hepatology.Explore the use of TIPS for aging patients, those with variceal bleeding, and major surgery candidates.FacultyVirginia Hernández-Gea (Moderator)Dominique Thabut (Faculty)Dhiraj Tripathi (Faculty)Thomas Krönc...2024-12-0536 min
EASL PodcastsEASL Studio Podcast: Alcohol, cardiometabolic risks factors, and steatotic liver disease – From stigma to breakthrough therapiesThis EASL Studio episode explores how alcohol worsens liver disease in patients with cardiometabolic risks, the stigma affecting diagnosis and care, and the latest therapeutic advances.Key topics of discussion include:Interaction between alcohol and cardiometabolic risksStigma and its impact on patient careIdentifying at-risk patients with clinical markersEmerging therapies and research opportunitiesFacultyAleksander Krag (Moderator)Fredrik Åberg (Faculty)Maru Rinella (Faculty)Maja Thiele (Faculty)This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.2024-11-2135 min
EASL PodcastsEASL Studio Podcast: What’s hot and not in liver transplantation: EASL CPG 2024 updateJoin the experts as they explore the new updates to the liver transplantation clinical practice guidelines, and delve into the latest advancement and ongoing challenges faced in this field.Tune in to:Discover cutting-edge techniques like machine perfusion and extended criteria grafts.Learn about new transplant indications, including oncology and acute liver failure.Understand challenges in immunosuppression and the management of chronic rejection.FacultyAhmed Elsharkawy (Moderator)Didier Samuel (Faculty)Julie Heimbach (Faculty)Sarwa Darwish (Faculty)Related episodesEASL Studio S4E13: JHEP Live: Liver transplantation for alcohol-related...2024-11-1444 min
EASL PodcastsEASL Studio Podcast: Why does WHO engagement with Steatotic Liver Disease matter?This episode is organised in collaboration with the Healthy Livers, Healthy Lives Coalition.FacultyJeffrey Lazarus (Moderator)Mazen Noureddin (Faculty)Shira Zelber-Sagi (Faculty)Kremlin Wickramasinghe (Faculty)The Healthy Livers, Healthy Lives Coalition’s activities are supported by Boehringer Ingelheim, Echosens, MSD, and Novo Nordisk.Our industry partners have had no input into the content of the Health Livers, Healthy Lives Coalition’s activities or this EASL Studio episode.Related episodesEASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio S6E7: The impact of p...2024-10-0336 min
EASL PodcastsEASL Studio Podcast: Is it time to abandon the use of ultrasound for HCC surveillance in MASLD?This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:Compares traditional ultrasound with advanced imaging techniques.Examines AI-based approaches in patient classification.The episode concludes with a forward-looking perspective on the future management of MASLD.FacultyThomas Berg (Moderator)Timm Denecke (Faculty)Juan-Manuel Pericàs (Faculty)Valérie Vilgrain (Faculty)This EASL Studio is supported by Bayer. EASL has re...2024-09-2649 min
EASL PodcastsEASL Studio Podcast: Are we relearning how to manage renal dysfunction in cirrhosis?Renal dysfunction is a significant concern for patients with liver cirrhosis, affecting nearly 50% of those hospitalised and leading to various complications that can reduce survival rates. Recently, the diagnostic criteria for acute kidney injury (AKI) and hepatorenal syndrome (HRS) have been updated to better capture the diversity and incidence of these conditions in cirrhotic patients.This episode of EASL Studio:Explores the updated definitions and standardisation of AKI in the context of cirrhosis.Reviews recent clinical trials, including ATTIRE and CONFIRM, and their implications for patient care.Provides a critical analysis of current and emerging strategies...2024-09-0538 min
Surfing the MASH TsunamiS5 - E23.1 - From The EASL Congress: Overview Of Challenges In Physician-Patient CommunicationCo-chairs Shira Zelber-Sagi and Mike Betel and panelists Tom Marjot and José Willemse, all from the EASL Congress session "Patient Experiences in Clinical Settings," join Louise Campbell to provide an overview of issues in physician-patient communication. The conversation itself has two elements. It starts with first-time surfers Tom Marjot and José Willemse introducing themselves to listeners. After that, Shira starts by discussing the EASL Congress session within the context of a broader collaboration called "EASL Patient Synergies." This program led to the creation of the Patient and Advocate Forum as the EASL Congress, which led to this prog...2024-07-1514 min
EASL PodcastsEASL Studio Podcast: Buongiorno Milano: What not to miss during EASL CongressEASL Studio - Buongiorno Milano: What not to miss during EASL Congress.FacultyAleksander Krag (Moderator)Debbie Shawcross (Faculty)Thomas Berg (Faculty)Ahmed Elsharkawy (Faculty)All EASL Studio Podcasts are available on EASL Campus.2024-06-1224 min
EASL PodcastsEASL Studio Podcast: Landmark studies at the EASL Congress 2024EASL Studio - Landmark studies at the EASL Congress 2024FacultyThomas Berg (Moderator)Rajiv Jalan (Faculty)Verena Keitel (Faculty)Frank Tacke (Faculty)All EASL Studio Podcasts are available on EASL Campus.2024-06-1245 min
EASL PodcastsEASL Studio Podcast: Education at the heart of EASL’s missionEASL Studio - Education at the heart of EASL’s missionFacultySven Francque (Moderator)Krista Rombouts (Faculty)Rajeshwar Mookerjee (Faculty)Henning Grønbæk (Faculty)All EASL Studio Podcasts are available on EASL Campus.2024-06-1224 minSurfing the MASH TsunamiS5 - E17.1 - Previewing EASL Congress 2024: Secretary General Aleksander Krag Shares His Vision For The CongressThis first conversation from our EASL Congress 2024 preview starts with EASL Secretary General Aleksander Krag offering his vision for next week's meeting in Milano, after which Hannes Hagstrom shares some of his thoughts about the meeting design. Aleksander starts by discussing the preparation that has gone into this Congress since the Vienna meeting closed last August. The goals are ambitious, but he feels EASL has, by and large, succeeded. Aleksander mentions that 7,000+ people have registered, including 80+ companies and 25+ patient groups. and that researchers submitted 3,000 abstracts, 2,000 of which have been accepted. "Almost 300 different types of sessions" with 450 faculty me...2024-06-0113 minSurfing the MASH TsunamiS5 - E17 - Previewing EASL Congress 2024 and its Major MASLD MomentsNext week, 7,000+ hepatology stakeholders will convene in Milano, Italy, to consume 2,000+ posters and presentations, including an extensive set of MASLD studies, at EASL Congress 2024. EASL Secretary General Aleksander Krag, Hannes Hagstrom, and Michelle Long join Jörn Schattenberg and Roger Green to preview the program.00:00:00 - Surf's Up: Season 5 Episode 17Standard lead-in, including quotes from panelists.00:02:40 - IntroductionRoger describes the structure of this episode.00:04:21 - Groundbreaker Good personal and professional news from the panelists. 00:08:04 - A 10,000m look at the EASL Congress 2024Aleksander discusses the preparation tha...2024-05-3059 min
EASL PodcastsEASL Studio Podcast: What‘s hot in viral hepatitis in 2024?This session covers a wide range of topics relevant to the current landscape of viral hepatitis, including elimination efforts, resistance to direct-acting antivirals (DAAs), surveillance methods during and after therapy. This talk provides you with valuable insights through an up-to-date overview of the latest developments and challenges in the field.FacultyThomas Berg (Moderator)Jordan Feld (Faculty)Norah Terrault (Faculty)Heiner Wedemeyer (Faculty)This episode is scheduled in honour of the United States’ Viral Hepatitis Awareness Month.This EASL Studio is supported by GSK and Vir Biotechnology. EASL has received no in...2024-05-3050 min
EASL PodcastsEASL Studio Podcast: Resmetirom: First approved drug for MASH, for whom and for how long?This episode explores the approval of resmetirom for NASH, analysing its integration into clinical practice and patient eligibility. The experts also discuss the role of lifestyle interventions alongside resmetirom, the use of biomarkers for patient selection, treatment monitoring, and the expected landscape changes over the next five years.FacultyAleksander Krag (Moderator)Naim Alkhouri (Faculty)Sven Francque (Faculty)Amalia Gastaldelli (Faculty)Related episodesSeason 5 , Episode 2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysEASL Studio from EASL Congress 2023: Steatotic liver disease global consensus...2024-05-1635 min
EASL PodcastsEASL Studio Podcast: YI Choice: Citizen science: Societal engagement in hepatologyThis episode aims at highlighting the importance of patient and public involvement in research. More precisely, the speakers focus on the importance of involving patients in research, practical steps to involve patients in research, and insights from EASL including engagement of patients in the EASL-Lancet Commission.FacultyMarta Alonso-Peña (Moderator)Kate Jack (Faculty)Marko Korenjak (Faculty)Thomas Marjot (Faculty)Related episodeEASL Studio from EASL Congress 2023: United we stand: Global societies collaborating to beat liver disease.All EASL Studio Podcasts are available on EASL Campus.2024-03-2831 min
EASL PodcastsEASL Studio Podcast: Therapy hierarchy in HCC: A new kid on the blockThis episode centres around an article recently published in the Journal of Hepatology, presenting a new treatment algorithm positioned as an evolution of the BCLC system and aimed at addressing its limitations in the staging and therapy hierarchy for HCC. This discussion covers the implications of this fresh approach in the management of HCC patients, challenging the standard paradigm.FacultyBruno Sangro (Moderator)Umberto Cillo (Faculty) Helen Reeves (Faculty)María Reig (Faculty)This EASL Studio is supported by AstraZeneca. EASL has received no input from AstraZeneca with regards to the content of th...2024-03-2140 min
EASL PodcastsEASL Studio Podcast: Is there a role for measuring blood ammonia in patients with cirrhosis?In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs.FacultyDebbie Shawcross (Moderator)Rajiv Jalan (Faculty)Sara Montagnese (Faculty)Elliot Tapper (Faculty)This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).Related...2024-03-1433 min
EASL PodcastsEASL Studio Podcast: The impact of policy measure in preventing liver diseases: The Hepahealth II studyThis episode treats of the Hepahealth II study, which aimed at estimating the impact of policy interventions targeting alcohol and obesity on the incidence of chronic liver disease and primary liver cancer in three European countries. Join our experts in their discussion of this study and of its conclusions.FacultyPatrizia Burra (Moderator)Maria Buti (Faculty)Peter Jepsen (Faculty)Shira Zelber-Sagi (Faculty)Related episodesEASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio from EASL Congress 2023: The battle to reduce alcohol harms… EASL’s new policyEASL Stud...2024-03-0731 min
EASL PodcastsEASL Studio Podcast: Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapyOn the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field.FacultyAleksander Krag (Moderator)Aftab Ala (Faculty)Pavel Strnad (Faculty)Alice Turner (Faculty)Related episodesEASL Studio from EASL Congress 2023: Clinical trials in rare diseases – opportunities and challengesEASL Studio from ILC 2022: Rare Liver Diseases – A growing landscape of oppo...2024-02-2935 min
EASL PodcastsEASL Studio Podcast: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?The definition of cACLD is now strongly linked to care and research outcomes such as non invasive diagnosis, reversibility and prevention of decompensation. Thus, what space is left for the use of the old term cirrhosis in clinical practice and research?FacultyPaolo Angeli (Moderator)Guadalupe Garcia-Tsao (Faculty)Valérie Paradis (Faculty)Thomas Reiberger (Faculty)Related episodesEASL Studio S5E5: JHEP Live: the new nomenclature for SLD: a multidisciplinary evaluation and approachEASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureEASL Studio S4E4: JHEP Live: I...2024-02-2231 min
EASL PodcastsEASL Studio Podcast: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyondIn this exclusive session, Thomas Berg and his panelists examine the intricate world of intrahepatic Cholangiocarcinoma (iCCA), following the publication of the EASL clinical practice guidelines on iCCA in 2023. This discussion aim at raising awareness and promoting a deeper understanding of this complex condition, while touching upon the topic of targeted therapies, highlighting the advancements and challenges that lie ahead.FacultyThomas Berg (Moderator)Katie Kelley (Faculty)Daniela Sia (Faculty)Juan Valle (Faculty)This episode is scheduled in honour of the World CCA Day (15 February) and the US CCA Awareness Month.2024-02-1545 min
EASL PodcastsEASL Studio Podcast: Do we solve MASLD by treating obesity?Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs’ current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists.Don’t miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management!FacultySven Francque (Moderator)Willem Pieter Brouwer (Faculty)Cyrielle Caussy (Faculty)Dimitris Papamargaritis (Faculty)This episode is scheduled following the United Kingdom’s National Obesity Awaren...2024-01-2533 min
EASL PodcastsEASL Studio Podcast: EASL Studio’s holiday reflection: A look back to leap forwardJoin us for a wrap-up of EASL Studio’s season and a preview of what is to come in 2024! In this special episode, we reminisce about the year’s top hepatology breakthroughs and controversies. This festive discussion highlights the best of the past while offering an exciting glimpse into the future of the evolving world of liver health.FacultyAleksander Krag (Moderator)Thomas Berg (Faculty)Ahmed Elsharkawy (Faculty)Debbie Shawcross (Faculty)All EASL Studio Podcasts are available on EASL Campus.2023-12-2127 min
EASL PodcastsEASL Studio Podcast: Hepatic encephalopathy: Underdiagnosed and underestimatedHepatic encephalopathy (HE) is a common reversible complication of advanced liver disease characterised by a spectrum of neuropsychiatric abnormalities. Due to its insidious onset, most patients only seek treatment once complications develop, resulting in it being an underdiagnosed and underestimated condition.This EASL Studio episode, organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN), explores the patient journey and treatment options.FacultyDebbie Shawcross (Moderator)Christian Labenz (Faculty)Steve Rodrigues (Faculty)Dominique Thabut (Faculty)This EASL Studio is supported by Norgine. EASL has received no input...2023-12-1435 min
EASL PodcastsEASL Studio Podcast: Basics in decision-making for liver cancer treatmentWith cases of hepatocellular carcinoma on the rise and representing the end stage of many chronic liver diseases, the treatment of liver cancer has become one of the most dynamic areas in hepatology. The focus of this episode is on answering practical clinical questions, examining trial data, and sharing clinical insights that may be useful for decision-making in daily clinical practice.FacultyTom Lüdde (Moderator)Christoph Roderburg (Faculty)Anna Saborowski (Faculty)Arndt Vogel (Faculty)This EASL Studio is supported by AstraZeneca and Eisai. EASL has received no input from AstraZeneca or Eisai w...2023-12-0733 min
EASL PodcastsEASL Studio Podcast: PSC and AIH overlap syndrome: does it actually exist?This episode explores key aspects of intriguing intersection of autoimmune liver diseases, such as their distinctive presentations in childhood and adulthood and the influence of inflammatory bowel disease on liver disease phenotypes. The speakers also examines the benefits and risks associated with immunosuppressive treatments in managing these complex conditions.FacultyPalak Trivedi (Moderator)Amanda Ricciuto (Faculty)Marianne Samyn (Faculty)Christoph Schramm (Faculty)This EASL Studio is supported by Chemomab Therapeutics. EASL has received no input from Chemomab Therapeutics with regards to the content of this programme.Related episodes...2023-11-3029 min
EASL PodcastsEASL Studio Podcast: The window hypothesis again, or just a closed window?The treatment of liver cirrhosis – currently based on symptomatic management of complications – has barely changed in last 20 years. In this episode, the experts discuss the use of statins, for which there is growing body of evidence of their beneficial effects in patients suffering with cirrhosis.FacultyThomas Reiberger (Moderator)Juan Gonzalez-Abraldes (Faculty)Elisa Pose (Faculty)Jonel Trebicka (Faculty)This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.Related episodesEASL Studio from EASL Cong...2023-11-2332 min
EASL PodcastsEASL Studio Podcast: Why should diabetologists care about the liver?In this episode, participants tackle the relationship between metabolic dysfunction-associated steatotic liver diseases (MASLD) and type 2 diabetes (T2D), exploring their prevalence and the potential for more aggressive outcomes. Experts weigh in on the pressing questions of whether non-invasive test thresholds should be adapted for MASLD patients with T2D and which drugs should take precedence as first-line treatments for high-risk MASLD cases.FacultyZobair Younossi (Moderator)Laurent Castera (Faculty)Camilla Dalby Hansen (Faculty)Amalia Gastaldelli (Faculty)This episode is scheduled according to the international calendar for the World Diabetes Day (14 November).2023-11-1636 min
EASL PodcastsEASL Studio Podcast: Alcohol and the new nomenclature – A game-changer?In honour of the Awareness Week on Alcohol related harm (21 November – 1 December), this episode discussed how the new nomenclature will affect healthcare pathways for those suffering with Alcohol-related liver diseases.Faculty Aleksander Krag (Moderator)Juan Pablo Arab (Faculty)Alexandre Louvet (Faculty)Maru Rinella (Faculty)Related episodes:EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureEASL Studio S4E8: The central role of alcohol and food policies on liver healthEASL Studio S3E5: JHEP Live: Stigma and alcoholAll EASL Studio Podcasts are available on EAS...2023-11-0937 min
EASL PodcastsJHEP Live: Hepatitis delta’s latest debate: Updates straight from EASL’s slateJoin the faculty as they take a deep dive into hepatitis delta (HDV) to:Shed light on the controversies surrounding this disease.Share their perspectives on the latest and most hotly debated recommendations.Discuss how these new recommendations will shape the future of research and patient care.FacultyThomas Berg (Moderator)Maurizia Brunetto (Faculty)Ohad Etzion (Faculty)Related episodes:EASL Studio S2E3: Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitorEASL Studio S2E8: Treatment of HBV-HDV coinfection in the era of...2023-11-0238 min
EASL PodcastsEASL Studio Podcast: Why bother with diet and exercise when an injection will suffice?During this episode, the experts discuss of what it really takes to implement a successful lifestyle modification in behavioural therapy. Tune in to learn tools and tips that can help treat patients in improving their liver health and quality of life.This episode was scheduled according to the international calendar for the World Food Day (16 October)FacultyShira Zelber Sagi (Moderator)Riccardo Dalle Grave (Faculty)Giulio Marchesini (Faculty)Related episodesEASL Studio S4E8: The central role of alcohol and food policies on liver healthEASL Studio S2E2...2023-10-1933 min
EASL PodcastsEASL Studio Podcast: JHEP Live: The new nomenclature for SLD: A multidisciplinary evaluation and approachIn this episode, the discussants examines the following questions, raised after a Journal of Hepatology’s nomenclature article:Is the introduction of metabolic risk factors (MRF) for the definition of MASLD justified?What are the main issues regarding the measurement and thresholds for MRFs?Is the introduction of the MetALD category clinically justified?Is it necessary to worry about MRFs in a patient drinking increased or excessive amounts of alcohol and if yes, how should these be accounted for in disease classification systems?FacultyVlad Ratziu (Moderator)Giulio Marchesini (Faculty)Nancy Reau (Faculty)Roberto Ve...2023-10-0531 minSurfing the MASH TsunamiS4-E42.1 - Sven Francque on Organizing the EASL SLD SummitThe EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD.In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews. The first featured interview is with Sven, who served as one of three organizing members for this year's Summit. In addition, Sven chaired both the opening and closing Plenary sessions on...2023-09-3011 min
EASL PodcastsEASL Studio Podcast: Highlights from the EASL SLD Summit 2023This EASL Studio episode covers the highlights of the SLD Summit 2023, including:Physiopathological mechanismProblems encountered in the cirrhotic stage in SLDNovelties about liver biopsiesFacultySven Francque (Moderator)Quentin Anstee (Faculty)Frank Tacke (Faculty)Maja Thiele (Faculty)Related episodesEASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysEASL Studio Live from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureEASL Studio S4E23: The conundrum of NASH: The growing global disease burden with low disease awarenessEASL Studio S4E22: JHEP...2023-09-2733 min
EASL PodcastsEASL Studio Podcast: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysThirty percent of the global population have too much fat in their liver. The big question is: are they really sick when most will not end up with liver disease?This episode discusses:How should they be assessed and by whom?What does this mean to healthcare systems?Are there downsides to systematic screening?FacultyAleksander Krag (Moderator)Alina Allen (Faculty)Manal El-Sayed (Faculty)Ian Rowe (FacultyRelated episodeEASL Studio Live from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureAll EASL Studio Podcasts are...2023-09-1435 min
EASL PodcastsEASL Studio Podcast: What is really new in the EASL CPG on ACLF?This #EASLStudio JHEP Live discusses the newly released EASL Clinical Practice Guidelines on Acute-on-chronic liver failure (ACLF).In particular:ICU admission criteria for patients with ACLFTreatment of infection and antibiotic selectionLiver supportLiver transplantation for ACLF: Sarcopenia and frailtyFacultyRichard Moreau (Moderator)Rajiv Jalan (Faculty)Constantine Karvellas (Faculty)Rakhi Maiwall (Faculty)All EASL Studio Podcasts are available on EASL Campus.2023-09-0739 min
EASL PodcastsEASL Studio Podcast: United we stand: Global societies collaborating to beat liver diseaseThis EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and is presenting the work of international liver societies to beat liver diseases.FacultyThomas Berg, EASL (Moderator)Marcelo Silva, ALEH (Faculty)Norah Terrault, AASLD (Faculty)Manal El-Sayed, SOLDA (Faculty)Shiina Shuichiro, APASL (Faculty)All EASL Studio Podcasts are available on EASL Campus.2023-08-1836 min
EASL PodcastsEASL Studio Podcast: Practice changing highlights from EASL Congress 2023This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and is covering practice changing following data presented during the congress.FacultyVirginia Hernández-Gea (Moderator)Ahmed Elsharkawy (Moderator)Maru Rinella (Faculty)Maria Reig (Faculty)Nancy Reau (Faculty)Verena Keitel (Faculty)All EASL Studio Podcasts are available on EASL Campus.2023-08-1729 min
EASL PodcastsEASL Studio Podcast: Steatotic liver disease global consensus to change nomenclatureThis EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and discusses the nomenclature change for steatotic liver disease.FacultyAleksander Krag, EASL (Moderator)Philip Newsome, EASL (Faculty)Maru Rinella, AASLD (Faculty)Graciela Castro-Narro, ALEH (Faculty)Mohamed El-Kassas, SOLDA (Faculty)Robert Mitchell-Thain, LPI (Faculty)Lorraine Stiehl, ALF (Faculty)All EASL Studio Podcasts are available on EASL Campus.2023-08-1737 min
EASL PodcastsEASL Studio Podcast: The battle to reduce alcohol harms… EASL’s new policyThis EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and discusses the newly released EASL policy statement on alcohol harm and related liver diseases. The document aims to highlight the extensive harm resulting from alcohol consumption and shine a light on the effective, yet underused, harm reduction policies available to European countries.FacultyFrank Murray Ireland (Moderator)Maria Buti (Moderator)Thomas Babor (Faculty)All EASL Studio Podcasts are available on EASL Campus.2023-08-1731 min
EASL PodcastsEASL Studio Podcast: Highlights of liver cancer research at EASL Congress 2023This EASL Studio Good Morning Vienna was live broadcast during the EASL Congress 2023 and is presenting the highlights of liver cancer research at the congress.FacultyJean-Charles Nault (Moderator)Josep Llovet (Moderator)Jessica Zucman-Rossi (Faculty)Bruno Sangro (Faculty)Matthias Pinter (Faculty)All EASL Studio Podcasts are available on EASL Campus.2023-08-1729 min
EASL PodcastsEASL Studio Podcast: EASL Congress 2023: Back to the futureThis EASL Studio Closing was live broadcast during the EASL Congress 2023 and discusses the future of hepatology.FacultyThomas Berg (Moderator)Aleksander Krag (Moderator)Tobias Böttler (Faculty)Debbie Shawcross (Faculty)All EASL Studio Podcasts are available on EASL Campus.2023-08-1728 minSurfing the MASH TsunamiS4-E34 - Drug Development Stories from EASL and ADA: Part 2This month, Surfing NASH embarks on a series of episodes dedicated to takeaways emerging from June's two major conferences: the 2023 EASL Congress in Vienna and the American Diabetes Association's 83rd Scientific Sessions meeting in San Diego. This is the second session focusing on drug development, and specifically, on several presentations for exciting drugs in development.This session kicks off with a twist as co-host Jörn Schattenberg introduces the episode and its panelists because Roger Green is late (he will join later with a bit of birthday banter). Joining this in-depth discussion around the latest d...2023-07-271h 04Surfing the MASH TsunamiS4-E21.4 - Virtual EASL Congress 2023 and the Power of PostersSurfing NASH offers an exciting preview of EASL Congress 2023 with new guest and EASL Vice-Secretary, Aleksander Krag, alongside EASL Educational Councillor, Sven Francque, and Surfers Jörn Schattenberg, Louise Campbell and Roger Green. The world’s largest liver meeting takes place 21-24 June in Vienna with an international faculty of experts from over 200 institutions. The diverse program will feature 2500 abstracts and be a uniquely momentous occasion for developing multidisciplinary approaches aimed at putting a major dent in Fatty Liver disease.This final session starts with Roger sharing his appreciation for conversational opportunities that emerge from poster presentations at...2023-05-2816 minSurfing the MASH TsunamiS4-E21.3 - Curating the EASL 2023 Program and 3 “Can’t Miss” FeaturesSurfing NASH offers an exciting preview of EASL Congress 2023 with new guest and EASL Vice-Secretary, Aleksander Krag, alongside EASL Educational Councillor, Sven Francque, and Surfers Jörn Schattenberg, Louise Campbell and Roger Green. The world’s largest liver meeting takes place 21-24 June in Vienna with an international faculty of experts from over 200 institutions. The diverse program will feature 2500 abstracts and be a uniquely momentous occasion for developing multidisciplinary approaches aimed at putting a major dent in Fatty Liver disease.This conversation starts with Roger’s question to Sven around his role as Educational Councillor and the vario...2023-05-2816 minSurfing the MASH TsunamiS4-E21.2 - Previewing EASL Congress 2023: Highlighting Exciting ElementsSurfing NASH offers an exciting preview of EASL Congress 2023 with new guest and EASL Vice-Secretary, Aleksander Krag, alongside EASL Educational Councillor, Sven Francque, and Surfers Jörn Schattenberg, Louise Campbell and Roger Green. The world’s largest liver meeting takes place 21-24 June in Vienna with an international faculty of experts from over 200 institutions. The diverse program will feature 2500 abstracts and be a uniquely momentous occasion for developing multidisciplinary approaches aimed at putting a major dent in Fatty Liver disease.This conversation begins with Jörn describing his anticipations for the meeting where he will be Chair of t...2023-05-2811 minSurfing the MASH TsunamiS4-E21.1 Meeting Aleksander Krag and Setting the Stage for EASL Congress 2023Surfing NASH offers an exciting preview of EASL Congress 2023 with new guest and EASL Vice-Secretary, Aleksander Krag, alongside EASL Educational Councillor, Sven Francque, and Surfers Jörn Schattenberg, Louise Campbell and Roger Green. The world’s largest liver meeting takes place 21-24 June in Vienna with an international faculty of experts from over 200 institutions. The diverse program will feature 2500 abstracts and be a uniquely momentous occasion for developing multidisciplinary approaches aimed at putting a major dent in Fatty Liver disease. In this conversation, the audience is introduced to Aleksander and his work in Fatty Liver disease. He des...2023-05-2813 min
EASL PodcastsEASL Studio Podcast: COST Actions: Opportunities for pan-European collaborations in liver diseasesCollaborations are key in achieving scientific progress. The European Horizon COST Actions provide great opportunities to build, grant, and/or participate in pan-European collaborations in multidisciplinary topics, including liver diseases.This EASL Studio:Provides you with information about the COST Action programme.Discusses the structure of the drug-induced liver injury (DILI) and cholangiocarcinoma (CCA) working groups.Highlights the potential for collaborative work within this programme.FacultyProf. Jesús Bañales (Moderator)Prof. Raul Andrade (Faculty)Dr Chiara Braconi (Faculty)Prof. Vincenzo Cardinale (Faculty)Related episodesS4E13: EA...2023-05-2532 min
EASL PodcastsEASL Studio Podcast: Promoting Liver Health: An urgent call for action at WHOOn 22 May 2023, policymakers, thought leaders, Permanent Mission Representatives to the UN, WHO staff, and people affected by liver disease will gather at the EASL Office in Geneva for the invitation-only event on the side-lines of the 76th World Health Assembly*: “Together for Better Liver Health: Mobilising Action for Fatty Liver Disease”. The aim of the event is to raise awareness on the need for action, and to call for a coordinated response to combat the global public health threat represented by fatty liver disease.Fatty liver disease is the most prevalent liver disease in history, affecting over one...2023-05-2429 minSurfing the MASH TsunamiS4-E21 - Surfing NASH Previews EASL Congress 2023Surfing NASH offers an exciting preview of EASL Congress 2023 with new guest and EASL Vice-Secretary, Aleksander Krag, alongside EASL Educational Councillor, Sven Francque, and Surfers Jörn Schattenberg, Louise Campbell and Roger Green. The world’s largest liver meeting takes place 21-24 June in Vienna with an international faculty of experts from over 200 institutions. The diverse program will feature 2500 abstracts and be a uniquely momentous occasion for developing multidisciplinary approaches aimed at putting a major dent in Fatty Liver disease. In this lively session, the group covers the following topics and more:2023-05-1851 min
EASL PodcastsEASL Studio Podcast: Highlights from the EASL Liver Cancer Summit 2023Watch this EASL Studio for highlights from the Liver Cancer Summit 2023.Discover:How artificial Intelligence is being used to increase knowledge in the field of liver cancer.New markers in hepatocellular carcinoma beyond ultrasound.Updates in the field cholangiocarcinoma and rare liver diseases… and much more!FacultyProf. Mathias Heikenwälder (Moderator)Prof. Josep Llovet (Faculty)Prof. Helen Reeves (Faculty)Related episodes:S3E16 – Liver cancer in 2022: Wrap-up & outlookS2E15 – JHEP Live – The best animal model for HCC — lost in translationSpecial Edition: Highlights of the Liver Cancer Summit 2022Policy Dialogues Episode 3...2023-04-2741 min
EASL PodcastsEASL Studio Podcast: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceThe EASL Policy Statement on liver cancer screening has recently been updated.In addition to addressing the updates, this episode of EASL Studio will discuss how risk-based surveillance of hepatocellular carcinoma (HCC) in patients suffering from cirrhosis is a cost effective strategy to increase benefits, reduce the harm of HCC surveillance.FacultyProf. Thomas Berg (Moderator)Mr. Pietro Fiocchi (Faculty)Prof. Peter Jepsen (Faculty)Mrs. José Willemse (Patient Perspective) All EASL Studio Podcasts are available on EASL Campus.2023-04-1942 min
EASL PodcastsEASL Studio Podcast: EASL-EF CLIF and EU Grants: Exploring novel mechanism and treatment of chronic liver failureThrough widespread multidisciplinary collaboration, consortia and EU grants provide unique opportunities to address critical questions.What opportunities exist for early career scientist?Which elements are essential for success?How have these partnerships contributed to advancements in the field?Watch this episode of EASL Studio to find out.FacultyProf. Thomas Berg (Moderator)Prof. Rajiv Jalan (Moderator)Prof. Minneke Coenraad (Faculty)Dr Cornelius Engelmann (Faculty)Prof. Pierre-Emmanuel Rautou (Faculty)Related episodeS4E2 YI Choice: How to build consortia and registriesAll EASL Studio Podcasts are available on...2023-04-1337 min
EASL PodcastsEASL Studio Podcast: Regenerating the liver graft with a machine?Machine perfusion is changing the status quo in liver transplantation by optimising the use of organs in times of organ shortage.Watch this EASL Studio to:Better understand the role of machine perfusion in liver transplantationUnderstand the optimal situations in machine perfusion is beneficialHave an overview of the different types of machines under evaluationFacultyProf. Marina Berenguer (Moderator)Prof. Pierre-Alain Clavien (Faculty)Dr Amelia Hessheimer (Faculty)Related episodesS3E8 – Transplanting patients with cancer – Is there a limit?S3E2 – Liver transplantation for ACLF: Opportunities, challenges, and pitfallsAll EA...2023-02-1629 min
EASL PodcastsEASL Studio Podcast: AI for DummiesThe field of artificial Intelligence (AI) is rapidly growing and derived technologies are technologies are increasingly being used in medical sciences to improve patient outcomes.What exactly is AI?How can it be beneficial?Why should AI be used in medicine?Watch this EASL Studio to find out.FacultyProf. Jakob Nikolas Kather (Moderator)Prof. Julien Calderaro (Faculty)Dr Arsela Prelaj (Faculty)Dr Tobias Seraphin (Faculty)Dr Katy Wack (Faculty)All EASL Studio Podcasts are available on EASL Campus.2023-02-0943 min
The Profluence Pod 🌐#14: Matt Beyer - CEO, Co-Founder East Asia Super League (EASL) | Building a sports league from scratch | Future of basketball | Importance of media + fan engagement | Asian sports ecosystemAfter several years of building a sports agency in China, Matt Beyer decided to start the East Asia Super League (EASL). It is the top basketball league in Asia, similar to the Champions League in European soccer.
The EASL combines the best Asian clubs and leagues with the goal of becoming one of the world’s top three professional basketball leagues by 2025.
Prior to building the EASL, Beyer spent time working for the NBA, as an agent, and in Chinese public relations. He speaks fluent Mandarin Chinese.
Chapters:
(01:30) Backstory of the EA...2023-02-0539 min
EASL PodcastsEASL Studio Podcast: A 360 approach to beat alcohol-related liver diseaseAlcohol is the main cause of advanced liver disease and a major cause of hospitalisation and disability across the globe, including Europe. In this EASL Studio you will hear the patient perspective from an individual who has overcome this disease and listen to the faculty discuss the measures that can help prevent it.FacultyProf. Ramon Bataller (Moderator)Prof. Giovanni Addolorato (Faculty)Prof. Peter Jepsen (Faculty)Prof. Debbie Shawcross (Faculty)Mrs Kristen Radage (Faculty)Mr. Steven Rodrigues (Patient Perspective)Related episodesS3E5: JHEP Live: Stigma and alcoholS3E4: Special Edition: Highlights...2023-01-2644 min
EASL PodcastsEASL Studio Podcast: Hepatitis B elimination: How far behind are we and what do we need to change to achieve it?In the first episode of EASL Studio season 4, the faculty looked at the current status of hepatitis B elimination and discussed what needs to be done to achieve it.FacultyDr Ahmed Elsharkawy (Moderator)Mr Danjuma K. Adda (Faculty)Prof. Maud Lemoine (Faculty)Prof. Jean-Michel Pawlotsky (Faculty)Dr John Ward (Faculty)Related episodesSpecial Edition: Live from Viral Hepatitis Elimination Conference 2022S3E2: Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitorS2E8: Treatment of HBV-HDV coinfection in the era of entry inhibitionAl...2023-01-1238 min
EASL PodcastsEASL Studio Podcast: Liver cancer in 2022: Wrap-up & outlookResults from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty discuss:why certain trials have failed whereas others have succeeded,what we have learned about the connection between overall survival and progression-free survival as endpoints, andhow the systemic therapy of HCC has evolved.FacultyProf. Peter Galle (Moderator)Prof. Bruno Sangro (Faculty)Dr Anna Saborowski (Faculty)Prof. Arndt Vogel (Faculty)Related episodesS2E15 – JHEP Live – The best animal model for HCC — lost in translationSpecial Edition: Highlights of the Liver Cancer Summit 2022Policy Dialogues Episode 3: Liver...2022-12-2234 min
EASL PodcastsEASL Studio Podcast: Chronic portal vein thrombosis: Anticoagulation and interventional radiology for all patients?In this episode of EASL Studio the experts discuss a non-cirrhotic portal vein thrombosis (PVT):What is PVT in the absence of cirrhosis,The role of interventional radiology in the management of portal cavernoma, andAn update from the VALDIG portal Vein Thrombosis meetingFacultyProf. Pierre-Emmanuel Rautou (Moderator)Prof. Juan-Carlos Garcia-Pagan (Faculty)Dr Aurélie Plessier (Faculty)All EASL Studio Podcasts are available on EASL Campus.2022-12-1525 min
EASL PodcastsEASL Studio Podcast: The future of hepatologyAs we near the end of 2022, this EASL Studio reflects upon:Which topics were most published aboutWhich fields will we focus on in 2023What will the future of hepatology look like?FacultyProf. Paolo Angeli (Moderator)Prof. Jessica Zucman-Rossi (Moderator)Prof. Thomas Berg (Faculty)Prof. Aleksander Krag (Faculty)All EASL Studio Podcasts are available on EASL Campus.2022-12-0831 min
EASL PodcastsEASL Studio Podcast: Regenerative Hepatology: From stem cells to tissue engineeringCurrently, the only established therapeutic option for end-stage liver disease is orthotopic liver transplantation. However, the paucity of donor organs limits this option to only a few patients. From liver stem cells to advanced tissue bioengineering, this episode of EASL Studio discusses regenerative hepatology techniques as an alternative treatment for patients.FacultyProf. Pedro Baptista (Moderator)Prof. Tobias Cantz (Faculty)Prof. Karen Piper Hanley (Faculty)Prof. Frederic Lemaigre (Faculty)Related episode:YI Choice: Propelling liver cell biology into the third dimensionAll EASL Studio Podcasts are available on EASL Campus.2022-11-1733 min
EASL PodcastsEASL Studio Podcast: Transplanting patients with cancer – Is there a limit?Listen to this EASL Studio to find out:Which policies for prioritisation exist within a deceased donor liver allocation system?What is the impact of novel cancer therapies on the selection of patients with prior cancer?FacultyProf. Sherrie Bhoori (Moderator)Prof. Pål-Dag Line (Faculty)Prof. Vincenzo Mazzaferro (Faculty)Prof. Gonzalo Sapisochin (Faculty)All EASL Studio Podcasts are available on EASL Campus.2022-10-3144 min
EASL PodcastsEASL Studio Podcast: How to improve end-of-life care in liver disease?In honour of World Hospice and Palliative Care Day (8 October), this EASL Studio episode examines:When is the best time to think about end-of-life care in liver disease?What does it mean for the liver care team?When and how should patients be referred to specialised palliative care?FacultyDr Patrizia Künzler-Heule (Moderator)Prof. Philip Larkin (Faculty)Dr Philip Berry (Faculty)All EASL Studio Podcasts are available on EASL Campus.2022-10-1333 min
EASL PodcastsEASL Studio Podcast: Special Edition: Highlights of EASL NAFLD Summit 2022This episode of EASL Studio discusses the latest data in the treatment of NAFLD presented at the EASL NAFLD Summit 2022.FacultyProf. Amalia Gastaldelli (Faculty)Prof. Frank Tacke (Faculty)Prof. Emmanuel Tsochatzis (Faculty)All EASL Studio Podcasts are available on EASL Campus.2022-09-2932 min
EASL PodcastsEASL Studio Podcast: Liver transplantation for ACLF: Opportunities, challenges and pitfallsThis EASL Studio discusses important issues related to the opportunities and challenges of liver transplantation in acute-on-chronic liver failure (ACLF).Does urgent liver transplantation improve the survival of patients with ACLF-3 and where are the limits?Are the current allocation systems adequate and how to implement ACLF criteria for prioritisation?The distinct lack of equity of access of ACLF-3 patients to liver transplantation: Where are the barriers?What data will the CHANCE study deliver to address some of the unanswered questions?FacultyProf. Rajiv Jalan (Moderator)Dr Thierry Artzner (Faculty)Prof. Luca Belli (Faculty...2022-09-1548 min
EASL PodcastsEASL Studio Podcast: JHEP Live: Covid vaccination and associated autoimmune hepatitis Several recent reports have postulated a link between autoimmune hepatitis (AIH) following SARS-CoV-2 infection or vaccination. This EASL Studio JHEP Live discuss the potential links between COVID-19 and AIH.FacultyProf. Vlad Ratziu (Moderator)Prof. Naga Chalasani (Moderator)Prof. Fernando Bril (Faculty)Prof. Robert Fontana (Faculty)Dr Johannes Hartl (Faculty)ℹ️ More information on the topic can be found in these articles:Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care, Rüther et al., J Hepatol. 2022 Jul; 77(1): 250–251SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis, Böttler et al...2022-09-0943 min
EASL PodcastsEASL Studio Podcast: How can our response to the climate crisis transform and improve hepatology services?Issues of climate change, global warming and sustainability are taking centre stage in political agendas across the globe, causing major restructuring in many sectors. But, what about the healthcare sector?How is climate change affecting healthcare?How big of a problem is climate change for liver care?What public health strategies can be implemented to mitigate the effects of climate change?You can find more information about the impact of climate change on liver disease care in this publication.Related podcast episodes: EASL Studio Podcast S2E12: Nurse and AHP Focus: Sustainable Hepatology – Ins...2022-06-3031 min
EASL PodcastsEASL Studio Podcast: EASL Haemochromatosis Guidelines 2022In honour of World Haemochromatosis week (1-7 June 2022) the newly updated EASL Clinical Practice Guidelines on Haemochromatosis will be discussed in this episode of EASL Studio.Read moreAll EASL Studio Podcasts are available on EASL Campus.2022-06-1643 min
EASL PodcastsEASL Studio Podcast - YI Choice: Propelling liver cell biology into the third dimensionReduce, Refine, Replace. Developed over 50 years ago, the 3Rs provide a framework that urges researchers to think carefully about methods used to investigate scientific questions. In this episode of EASL Studio, we took a closer look at the third R, Replace. With the World Day for Laboratory Animals fast approaching, we discussed how to propel liver cell biology into the third dimension.What are the advantages of 3D cultures?Can liver cell types be studied in representative manner using 3D cultures?More importantly, which part of animal research can be replaced by 3D cell culture experiments?This...2022-04-2138 min
EASL PodcastsEASL Studio Podcast: Should anticoagulants be given to patients with cirrhosis to improve outcome?Discover this EASL Studio Podcast highlighting the recently published EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. Join the faculty as they discuss:What effects do anticoagulants have on survival and liver related events in cirrhosis?What are the mechanisms of action?What type of anticoagulants should be used in patients with cirrhosis?Read moreAll EASL Studio Podcasts are available on EASL Campus.2022-04-0530 min
EASL PodcastsEASL Studio Podcast S2E1 - New treatment options for hereditary cholestasis syndromes: A game-changer?This podcast is based on the EASL Studio episode hosted on the occasion of the Rare Liver Diseases Month.This episode focused on rare liver diseases, in particular, Progressive Familial Intrahepatic Cholestasis (PFIC). Discussions covered:Clinical presentation of PFICCurrent therapeutic optionsThe introduction of IBAT/ASBT inhibitors and their impactClinical trialsOrphan drugs approved for PFICInterview with EMA on the orphan drug programmeThis EASL Studio episode was supported by Albireo Pharma and Mirum Pharmaceuticals.Read more: https://easlcampus.eu/podcasts/easl-studio-podcast-s2e1-new-treatment-options-hereditary-cholestasis-syndromes-game-changer2022-04-0551 min
EASL PodcastsEASL Studio Podcast S2E3 - Interview with Stephan Urban - From bench to bedside: Process of developing the first HBV/HDV entry inhibitorIn this EASL Studio Podcast, a very special interview with Prof. Stephan Urban talking about his journey of the discovery and development of the first HBV/HDV entry inhibitor.Where did the story begin and what were the major breakthroughs and challenges?What are the mechanisms of viral entry inhibitors and how it differs from direct acting antivirals mode of action?How does it impact the future of HBV/HDV treatment landscape?This project has been made possible with the provision of a financial grant from Gilead Sciences Europe Ltd.EASL has received no input from...2022-04-0541 min
EASL PodcastsEASL Studio Podcast: Betablockers in cirrhosis: Has Baveno consensus gone too far?Discover this EASL Studio podcast discussing the Baveno Consensus started over 30 years ago with the aim of reviewing current diagnostic and therapeutic strategies and producing updated definitions.But, with the extension of indication of non-selective beta blockers, has the consensus gone too far?Is there enough evidence for their use in already decompensated patients?How safe are they in this patient population?What do we know about the effects on refractory ascites? Circulatory dysfunction?Read moreAll EASL Studio Podcasts are available on EASL Campus.2022-04-0531 min